ALDH2 Variant Drives Thrombosis Risk. 11/23/25

Welcome to Cardiology Today – Recorded November 23, 2025. This episode summarizes 5 key cardiology studies on topics like calcified mitral valve disease and platelet activation. Key takeaway: ALDH2 Variant Drives Thrombosis Risk.. Article Links: Article 1: Clinical Presentation and Mid-Term Results of Mitral Valve Surgery for Calcified Mitral Valve Disease – The MITRACURE registry. (The Canadian journal of cardiology) Article 2: Coronary microvascular dysfunction in patients with acute coronary syndrome and non-obstructive coronary artery disease: a 10-year clinical follow-up study. (International journal of cardiology) Article 3: Vasostatin-2 attenuates injury-induced neointimal hyperplasia through the ACE2/MasR/PPARγ/NR1D1/Gas1 axis. (Cardiovascular research) Article 4: ALDH2 rs671 variant enhances platelet activation and thrombosis by disrupting mitochondrial complex I assembly. (Cardiovascular research) Article 5: Vascular regenerative deficiencies in people with elevated lipoprotein(a): the Lp(a)-VRCE CardioLink-16 translational study. (Cardiovascular research) Full episode page: https://podcast.explainheart.com/podcast/aldh2-variant-drives-thrombosis-risk-11-23-25/ Featured Articles Article 1: Clinical Presentation and Mid-Term Results of Mitral Valve Surgery for Calcified Mitral Valve Disease – The MITRACURE registry. Journal: The Canadian journal of cardiology PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41274561 Summary: The MITRACURE registry, a large multicenter observational study conducted in France and Canada, includes 3522 patients. Within this registry, patients diagnosed with calcified mitral valve disease were matched 4 to 1 for age, sex, and concomitant procedures with individuals experiencing myxomatous mitral valve disease. This registry provides real-world information on the characteristics and mid-term outcomes of patients with calcified mitral valve disease undergoing mitral valve surgery, addressing a condition recognized for its specific management challenges. Article 2: Coronary microvascular dysfunction in patients with acute coronary syndrome and non-obstructive coronary artery disease: a 10-year clinical follow-up study. Journal: International journal of cardiology PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41274583 Summary: Previous studies reported that patients with myocardial infarction and non-obstructive coronary arteries (MINOCA) experienced adverse clinical outcomes. This study specifically assessed coronary blood flow velocity response to ergonovine, adenosine, and the cold pressor test using transthoracic Doppler echocardiography. This non-invasive assessment of coronary functional abnormalities was conducted to determine its predictive value for long-term prognosis over a 10-year clinical follow-up period in this patient population. Article 3: Vasostatin-2 attenuates injury-induced neointimal hyperplasia through the ACE2/MasR/PPARγ/NR1D1/Gas1 axis. Journal: Cardiovascular research PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41231769 Summary: Vasostatin-2, a bioactive peptide with established cardiovascular-protective and anti-inflammatory properties, attenuates injury-induced neointimal hyperplasia. This study determined that Vasostatin-2 achieves this attenuation through a specific molecular mechanism involving the Angiotensin-converting enzyme 2, Mas receptor, Peroxisome proliferator-activated receptor gamma, Nuclear Receptor Subfamily 1 Group D Member 1, and Growth arrest specific 1 axis. The research found this peptide influences vascular remodeling following injury and is relevant to restenosis in patients after percutaneous coronary intervention. Article 4: ALDH2 rs671 variant enhances platelet activation and thrombosis by disrupting mitochondrial complex I assembly. Journal: Cardiovascular research PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41150615 Summary: The Aldehyde Dehydrogenase 2 rs671 variant, a prevalent loss-of-function mutation observed in 30 to 50 percent of East Asian populations, significantly diminishes Aldehyde Dehydrogenase 2 enzymatic activity by 60 to 90 percent. This variant enhances platelet activation and thrombosis, directly contributing to an elevated thrombotic risk. The study determined that this prothrombotic effect occurs specifically through the disruption of mitochondrial complex one assembly. Article 5: Vascular regenerative deficiencies in people with elevated lipoprotein(a): the Lp(a)-VRCE CardioLink-16 translational study. Journal: Cardiovascular research PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40883226 Summary: Elevated lipoprotein(a) directly results in vascular regenerative deficiencies. Lipoprotein(a) is an established causal risk factor for atherosclerotic cardiovascular disease. This study found that elevated levels of lipoprotein(a) modify vascular regenerative cell content properties, impacting the capacity for vascular repair. Depletion of vascular regenerative progenitor cells serves as an indicator of compromised vascular repair in individuals with cardiometabolic disorders. Transcript Today’s date is November 23, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Clinical Presentation and Mid-Term Results of Mitral Valve Surgery for Calcified Mitral Valve Disease – The MITRACURE registry. The MITRACURE registry, a large multicenter observational study conducted in France and Canada, includes 3522 patients. Within this registry, patients diagnosed with calcified mitral valve disease were matched 4 to 1 for age, sex, and concomitant procedures with individuals experiencing myxomatous mitral valve disease. This registry provides real-world information on the characteristics and mid-term outcomes of patients with calcified mitral valve disease undergoing mitral valve surgery, addressing a condition recognized for its specific management challenges. Article number two. Coronary microvascular dysfunction in patients with acute coronary syndrome and non-obstructive coronary artery disease: a 10-year clinical follow-up study. Previous studies reported that patients with myocardial infarction and non-obstructive coronary arteries (MINOCA) experienced adverse clinical outcomes. This study specifically assessed coronary blood flow velocity response to ergonovine, adenosine, and the cold pressor test using transthoracic Doppler echocardiography. This non-invasive assessment of coronary functional abnormalities was conducted to determine its predictive value for long-term prognosis over a 10-year clinical follow-up period in this patient population. Article number three. Vasostatin-2 attenuates injury-induced neointimal hyperplasia through the ACE2/MasR/PPARγ/NR1D1/Gas1 axis. Vasostatin-2, a bioactive peptide with established cardiovascular-protective and anti-inflammatory properties, attenuates injury-induced neointimal hyperplasia. This study determined that Vasostatin-2 achieves this attenuation through a specific molecular mechanism involving the Angiotensin-converting enzyme 2, Mas receptor, Peroxisome proliferator-activated receptor gamma, Nuclear Receptor Subfamily 1 Group D Member 1, and Growth arrest specific 1 axis. The research found this peptide influences vascular remodeling following injury and is relevant to restenosis in patients after percutaneous coronary intervention. Article number four. ALDH2 rs671 variant enhances platelet activation and thrombosis by disrupting mitochondrial complex I assembly. The Aldehyde Dehydrogenase 2 rs671 variant, a prevalent loss-of-function mutation observed in 30 to 50 percent of East Asian populations, significantly diminishes Aldehyde Dehydrogenase 2 enzymatic activity by 60 to 90 percent. This variant enhances platelet activation and thrombosis, directly contributing to an elevated thrombotic risk. The study determined that this prothrombotic effect occurs specifically through the disruption of mitochondrial complex one assembly. Article number five. Vascular regenerative deficiencies in people with elevated lipoprotein(a): the Lp(a)-VRCE CardioLink-16 translational study. Elevated lipoprotein(a) directly results in vascular regenerative deficiencies. Lipoprotein(a) is an established causal risk factor for atherosclerotic cardiovascular disease. This study found that elevated levels of lipoprotein(a) modify vascular regenerative cell content properties, impacting the capacity for vascular repair. Depletion of vascular regenerative progenitor cells serves as an indicator of compromised vascular repair in individuals with cardiometabolic disorders. Thank you for listening. Don’t forget to subscribe. Keywords calcified mitral valve disease, platelet activation, cardiometabolic disorders, transthoracic Doppler echocardiography, percutaneous coronary intervention, thrombosis, myxomatous mitral valve disease, MITRACURE registry, long-term prognosis, lipoprotein(a), Vasostatin-2, rs671 variant, Mas receptor, coronary microvascular dysfunction, mitral valve surgery, myocardial infarction and non-obstructive coronary arteries, neointimal hyperplasia, mitochondrial complex one, Aldehyde Dehydrogenase 2, progenitor cells, Angiotensin-converting enzyme 2, atherosclerotic cardiovascular disease, vascular regeneration. About Concise summaries of cardiovascular research for professionals. Subscribe • Share • FollowThe post ALDH2 Variant Drives Thrombosis Risk. 11/23/25 first appeared on Cardiology Today.